Abstract:In order to efficiently control the progression of atherosclerosis, 37pA‐LNP/6877002 and 37pA‐PtLNP are constructed to regulate the plaque microenvironment. 37pA‐PtLNP can effectively scavenge intracellular reactive oxygen species (ROS) of inflammatory macrophage in plaque. 37pA‐LNP/6877002 can inhibit the activities of tumor necrosis factor receptor‐associated factor 6 (TRAF6) to modestly decrease the proportion of the proinflammatory macrophage phenotype (reduce the expression of CD86 and iNOS). The combination of 37pA‐PtLNP and 37pA‐LNP/6877002 can achieve satisfactory stabilization of plaques with minimal progression. Chronic inflammatory microenvironment is the predominant milieu that promotes the progression of atherosclerosis (AS). However, targeted regulation of the chronic proinflammatory milieu still needs to be improved. In this study, macrophage‐targeting nanosystems composed of 37pA peptide embedded–Pt lipid nanoparticles (37pA‐PtLNP) and tumor necrosis factor‐associated factor 6 (TRAF6) inhibitor (6877002)‐loaded poly(ε‐caprolactone)‐b‐polyethylene glycol‐b‐poly(ε‐caprolactone) (PCEC) are constructed with 37pA peptide embedded–lipid coating (37pA‐LNP/6877002), to stabilize atherosclerotic lesions. The cooperative regulation effects of these nanosystems in achieving reactive oxygen species (ROS) scavenging and inflammatory signaling inhibition are investigated. 37pA‐PtLNP effectively scavenges several ROS, however, also promotes the expression of iNOS. The introduction of 37pA‐LNP/6877002 inhibits the activities of TRAF6, a downstream intracellular factor of the CD40L‐CD40‐TRAF6 axis, to decrease the proportion of the proinflammatory M1 macrophage phenotype, which is further downregulated by combined treatment with 37pA‐PtLNP. The combination of 37pA‐PtLNP and 37pA‐LNP/6877002 not only counteracts 37pA‐PtLNP–induced iNOS upregulation but also alleviates the chronic inflammatory microenvironment by reducing the expression of proinflammatory cytokines and chemokines. The anti‐AS efficacy in vivo on ApoE−/− mice further demonstrates that the combination of 37pA‐PtLNP and 37pA‐LNP/6877002 targetedly modulates the atherosclerotic plaque microenvironment, achieving stabilization of lesions with minimal progression. This study provides a promising strategy for AS management.

Synthetic CD47 antibody-chitosan/hyaluronic acid polyelectrolyte complex mediates targeted inhibition of atherosclerotic plaques by exogenous foam-like cells via the NLRP3 pathway

Synthesis and characterization of atherosclerotic target anti-CD47 functionalized by nano-polyelectrolyte complexes between chitosan and hyaluronic acid and in vivo and in vitro targeting experiments

CD47-SIRPα signaling-inspired engineered monocytes for preventing the progression of atherosclerotic plaques

Platelet Membrane-Coated Nanocarriers Targeting Plaques to Deliver Anti-CD47 Antibody for Atherosclerotic Therapy

ROS-responsive Biomimetic Nanovesicles to Plaque Microenvironment in Targeted Therapy of Atherosclerosis

Intracellular and Extracellular Synergistic Therapy for Restoring Macrophage Functions Via Anti-Cd47 Antibody-Conjugated Bifunctional Nanoparticles in Atherosclerosis

Theranostic nanoplatform to target macrophages enables the inhibition of atherosclerosis progression and fluorescence imaging of plaque in ApoE(−/−) mice

Enhanced Macrophages Engulfment by Peptide‐Templated Nanoassemblies Targeting SIRPα and Suppressing Oxidative Stress for Atherosclerosis Pro‐Efferocytotic Therapy

Chitosan and Hyaluronic Acid Nanopolyelectrolyte Combined with Tanshinone IIA Targets Signal Transduction Pathway to Prevent Atherosclerosis

Targeting Nanoplatform for Atherosclerosis Inhibition and Degradation via a Dual‐Track Reverse Cholesterol Transport Strategy

Research_9845459 1..12

Simultaneously Blocking ANGPTL3 and CD47 Prevents the Progression of Atherosclerosis Through Regulating Lipid Metabolism, Macrophagic Efferocytosis and Lipid Peroxidation

CD47‐ and Integrin α 4/ β 1‐Comodified‐Macrophage‐Membrane‐Coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque

CD47‐ and Integrin Α4/β1‐comodified‐macrophage‐membrane‐coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque

Plaque Macrophage‐Targeting Nanosystems with Cooperative Co‐Regulation of ROS and TRAF6 for Stabilization of Atherosclerotic Plaques

Targeted nanoparticles triggered by plaque microenvironment for atherosclerosis treatment through cascade effects of reactive oxygen species scavenging and anti-inflammation

Modulating Plaque Inflammation <i>via</i> Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis

Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect

Phagocytosis of polymeric nanoparticles aided activation of macrophages to increase atherosclerotic plaques in ApoE−/− mice

Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis

CD47‐ and Integrin Α4/β1‐comodified‐macrophage‐membrane‐coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque (adv. Healthcare Mater. 4/2022)